专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012158818A2 MULTI-SPECIFIC FAB FUSION PROTEINS AND METHODS OF USE 审中-公开
标题翻译：多特异性FAB融合蛋白及其使用方法
公开(公告)号：WO2012158818A2
公开(公告)日：2012-11-22
申请号：PCT/US2012038177
申请日：2012-05-16
申请人： FABION PHARMACEUTICALS INC , ZHOU HONGXING
发明人： ZHOU HONGXING
CPC分类号： C07K16/2809 , C07K14/705 , C07K16/30 , C07K2317/31 , C07K2317/55 , C07K2319/00 , C07K2319/74
摘要： The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.
摘要翻译：本公开一般涉及多特异性Fab融合蛋白（MSFP），其包含与融合部分（融合部分A或B）融合的N-末端的抗体Fab片段。包含Fab片段的MSFP显示出Fab片段与Fab靶标的结合能力显着降低。当通过将融合部分与其靶标结合将MSFP聚集在细胞表面上时，还原Fab与靶标的结合。 Fab与其靶的减少的结合，特别是当呈现在其天然状态的细胞表面时，没有融合部分结合提供了优点，例如：减少的副作用并且以受控的方式允许选择性和特异性的期望的药理作用。

2. 发明申请

WO2012158818A3 MULTI-SPECIFIC FAB FUSION PROTEINS AND METHODS OF USE 审中-公开
公开(公告)号：WO2012158818A3
公开(公告)日：2012-11-22
申请号：PCT/US2012/038177
申请日：2012-05-16
申请人： FABION PHARMACEUTICALS, INC. , ZHOU, Hongxing
发明人： ZHOU, Hongxing
IPC分类号： C07K16/46 , C12N15/62 , A61K39/395 , A61P35/00
摘要： The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.

3. 发明公开

EP2710042A2 MULTI-SPECIFIC FAB FUSION PROTEINS AND METHODS OF USE 审中-公开
标题翻译：多特异性FAB融合蛋白及其使用方法
公开(公告)号：EP2710042A2
公开(公告)日：2014-03-26
申请号：EP12785857.9
申请日：2012-05-16
申请人： Fabion Pharmaceuticals, Inc.
发明人： ZHOU, Hongxing
IPC分类号： C07K16/46 , C12N15/62 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2809 , C07K14/705 , C07K16/30 , C07K2317/31 , C07K2317/55 , C07K2319/00 , C07K2319/74
摘要： The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式